SIGA - NASDAQ
SIGA Technologies, Inc.
$4.29
-0.69%SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
At a Glance
Live Snapshotsiga
Cash and Short Term Investments
Last Annual Value
154.97M
3-Year CAGR
16%
5-Year CAGR
6%
10-Year CAGR
3%
SIGA Technologies, Inc. Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
SIGA Technologies, Inc. NASDAQ:SIGA | 154.97M | 1.1% | 8.5% | 18.4% | |
 Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | 154.96M | 39.6% | 4.4% | 7.6% | |
 Aquestive Therapeutics, Inc. NASDAQ:AQST | 121.17M | 71.9% | 34.0% | 29.4% | |
 Ventyx Biosciences, Inc. NASDAQ:VTYX | 217.32M | -4.8% | -3.4% | N/A | |
 Esperion Therapeutics, Inc. NASDAQ:ESPR | 167.85M | 26.8% | -8.3% | 16.0% | |
 DarioHealth Corp. NASDAQ:DRIO | 26.25M | -10.7% | -6.1% | 34.9% | |
 Emergent BioSolutions Inc. NYSE:EBS | 205.40M | 22.5% | -18.6% | -2.8% | |
 CytomX Therapeutics, Inc. NASDAQ:CTMX | 137.05M | -7.7% | -14.8% | -2.8% | |
 Olema Pharmaceuticals, Inc. NASDAQ:OLMA | 505.44M | 24.5% | 12.0% | N/A | |
 Organogenesis Holdings Inc. NASDAQ:ORGO | 93.68M | -3.5% | -3.8% | 56.8% |
SIGA Technologies, Inc. Fair Value Envelope
Related Guides
Continue your SIGA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.